Enlivex Therapeutics Ltd. (ENLV)

NASDAQ: ENLV · IEX Real-Time Price · USD

1.322

-0.058 (-4.20%)

At close: Jul 2, 2024, 3:59 PM

1.320

-0.002 (-0.15%)

After-hours: Jul 2, 2024, 7:53 PM EDT

Enlivex Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2012
Selling, General & Admin	6.14	7.1	6.41	3.7	3.02	Upgrade
Research & Development	19.01	18.69	12.88	6.09	5.6	Upgrade
Other Operating Expenses	4.24	0	0	0	0	Upgrade
Operating Expenses	29.4	25.8	19.29	9.79	8.62	Upgrade
Operating Income	-29.4	-25.8	-19.29	-9.79	-8.62	Upgrade
Interest Expense / Income	-0.33	5.26	-4.82	0	0	Upgrade
Other Expense / Income	-	-	-	2.04	0.77	Upgrade
Pretax Income	-29.07	-31.06	-14.47	-11.82	-9.38	Upgrade
Net Income	-29.07	-31.06	-14.47	-11.82	-9.38	Upgrade
Shares Outstanding (Basic)	19	18	18	13	9	Upgrade
Shares Outstanding (Diluted)	19	18	18	13	9	Upgrade
Shares Change	0.98%	3.00%	35.62%	52.25%	146.47%	Upgrade
EPS (Basic)	-1.56	-1.69	-0.81	-0.90	-1.11	Upgrade
EPS (Diluted)	-1.56	-1.69	-0.81	-0.90	-1.11	Upgrade
Free Cash Flow	-23.63	-32.08	-19.17	-12.03	-7.23	Upgrade
Free Cash Flow Per Share	-1.27	-1.74	-1.07	-0.91	-0.84	Upgrade
EBITDA	-28.56	-25.02	-18.74	-11.54	-9.01	Upgrade
Depreciation & Amortization	0.84	0.78	0.55	0.29	0.37	Upgrade
EBIT	-29.4	-25.8	-19.29	-11.82	-9.38	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).